Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Clinical Efficacy Study Of An Oral Tyrosine Kinase Inhibitor Of VEGFR-2 To Treat Recurrent Or Persistent Small-Volume Epithelial Ovarian Cancer, Primary Peritoneal Serous Cancer, Or Fallopian Tube Cancer

NCT00074867 is registered in ClinicalTrials.gov with Pfizer as lead sponsor.

NCT NCT00074867
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00074867 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Clinical Efficacy Study Of An Oral Tyrosine Kinase Inhibitor Of VEGFR-2 To Treat Recurrent Or Persistent Small-Volume Epithelial Ovarian Cancer, Primary Peritoneal Serous Cancer, Or Fallopian Tube Cancer
Lead sponsor
Pfizer
Phase
Phase 2
Overall status
Completed
Start date
October 31, 2003
Completion date
September 30, 2004
Enrollment
29
Sites
9

Conditions

As the registry lists them; a condition with its own page is linked.

fallopian tube neoplasms, ovarian neoplasms, peritoneal neoplasms